Eton Pharmaceuticals, Inc. Operating Lease Cost
Eton Pharmaceuticals, Inc. (ETON) reported Operating Lease Cost of $85.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseCost · last filed 2026-08-13
- Eton Pharmaceuticals, Inc. operating lease, cost for the quarter ending 2026-06-30 was $61.00K, a 205.00% increase year-over-year.
- Eton Pharmaceuticals, Inc. operating lease, cost for the quarter ending 2026-03-31 was $24.00K, a 9.09% increase year-over-year.
- Eton Pharmaceuticals, Inc. operating lease, cost for the quarter ending 2025-09-30 was -$6.00K, a 127.27% decline year-over-year.
- Eton Pharmaceuticals, Inc. operating lease, cost for the quarter ending 2025-06-30 was $20.00K, a 5.26% increase year-over-year.
| Period end | Operating Lease, Cost 3 month | Operating Lease, Cost 6 month | Operating Lease, Cost 6 month as first filed | Operating Lease, Cost 9 month |
|---|---|---|---|---|
| 2026-06-30 | $61.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $85.00K 10-Q · filed 2026-08-13 | ||
| 2026-03-31 | $24.00K 10-Q · filed 2026-05-14 | |||
| 2025-09-30 | -$6.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $14.00K derived: sum of 2 quarters · filed 2026-08-13 | $36.00K 10-Q · filed 2025-11-06 | |
| 2025-06-30 | $20.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $42.00K 10-Q · filed 2026-08-13 | $43.00K 10-Q · filed 2025-08-07 | |
| 2025-03-31 | $22.00K 10-Q · filed 2026-05-14 | |||
| 2024-09-30 | $22.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $41.00K derived: sum of 2 quarters · filed 2025-11-06 | $61.00K 10-Q · filed 2025-11-06 | |
| 2024-06-30 | $19.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $39.00K 10-Q · filed 2025-08-07 | ||
| 2024-03-31 | $20.00K 10-Q · filed 2025-05-13 | |||
| 2023-09-30 | $57.00K 10-Q · filed 2024-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |